Opioid-sparing effect of diclofenac in cancer pain

Journal of Pain and Symptom Management

Volumn 14, Issue 1, 1997, Pages 15-20

  Mercadante, Sebastiano ^c   Sapio, Monica ^d   Caligara, Marina ^b   Serretta, Roberto ^d   Dardanoni, Gabriella ^a   Barresi, Luca ^d  

^a Epidemiologic Observatory of Sicily   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAMOT Onlus   (Italy)

^d NONE

Author keywords

Cancer pain; Diclofenac; Methadone; NSAIDs; Opioids; Patient controlled analgesia

Indexed keywords

DICLOFENAC; METHADONE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; PATIENT CONTROLLED ANALGESIA;

AGED; ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DRUG SYNERGISM; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; METHADONE; MIDDLE AGED; NEOPLASMS; PAIN; PALLIATIVE CARE;

EID: 0030838001     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(97)00005-5     Document Type: Article

References (28)

1. De Conno F, Ripamonti C, Sbanotto A, Saita L, Zecca E, Ventafridda V. The pharmacological management of cancer pain. Part 1: the role of non opioid and adjuvant drugs. Ann Oncol 1993;4:187-193.
2. Eisemberg E, Berkey CS, Carr DB, Mosateller F, Chalmers C. Efficacy and safety of nonsteroidal antinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994;12:2756-2765.
3. Pace V. Use of nonsteroidal anti-inflammatory drugs in cancer. Palliat Med 1995;9:273-286.
4. Mercadante S, Maddaloni S, Roccella S, Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain 1992;50:151-155.
5. Rawlins MD. Non-opioid analgesics. In: Doyle D, Hanks GW, MacDonald N, eds. Oxford textbook of palliative medicine. Oxford: Oxford Medical Publications, 1993, 182-187.
6. Burns JW, Aitken HA, Bullingam RES, McArdle CS, Kenny GNC. Double-blind comparison of the morphine sparing effect of continuous and intermittent IM administration of ketorolac. Br J Anaesth 1991;67:235-238.
7. Moffat AC, Kenny GNC, Prentice JW. Postoperative nefopam and diclofenac: evaluation on their morphine-sparing effect after upper abdominal surgery. Anesthesia 1990;45:302-305.
8. Bjorkman R, Ulman A, Hedner J. Morphine-sparing effect of diclofenac in cancer pain. Eur J Clin Pharmacol 1993;44:1-5.
9. Schmidt N, Sittl R, Brune K, Geisslinger G. Rapid determination of methadone in plasma, cerebrospinal fluid, and using by gas chromatography and its application to routine drug monitoring. Pharmacol Res 1993;10:441-444.
10. Jurna I, Brune K. Central effect of the non-steroid anti-inflammatory agents, indomethacin, ibuprofen, and diclofenac, determined in C fibre-evoked activity in single neurones of the rat thalamus. Pain 1990;41:71-80.
11. Ashburn MA, Lipman AG. Management of pain in the cancer patient. Anesth Analg 1993;76:402-416.
12. Dellemijn PLI, Verbiest HBC, Van Vliet JJ, Roos PJ, Vecht CJ. Medical therapy of malignant nerve pain: a randomized double-blind exploratory trial with naproxen versus slow release morphine. Eur J Cancer 1994;30:1244-1250.
13. De Conno F, Ripamonti C, Bianchi M, Ventafridda V, Panerai AE. Diclofenac does not modify morphine bioavailability in cancer patients. Pain 1992;48:401-402.
14. Ventafridda V, Toscani F, Tamburini M, et al. Sodium naproxen versus sodium diclofenac in cancer pain control. Drug Res 1990;40:1132-1134.
15. Minotti V, Patoia L, Roila F, et al. Double-blind evaluation of analgesic efficacy of orally administered diclofenac, nefopam and acetylsalicylic acid (ASA) plus codeine in chronic cancer pain. Pain 1989;36:177-183.
16. Bjorkman R, Ullman A, Hedner J. Morphine-sparing effect of diclofenac in cancer pain. Eur J Clin Pharmacol 1993;44:1-5.
17. Mercadante S, Genovese G, Kargar JA, et al. Home palliative care: results in 1991 versus 1988. J Pain Symptom Manage 1992;7:414-418.
18. Ventafridda V, De Conno F, Panerai AE, Maresca V, Monza GC, Ripamonti C. Non-steroidal anti-inflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs. J Intern Med Res 1990;18:21-29.
19. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993;52:137-147.
20. Hammack JE, Loprinzi CL. Use of orally administered opioids for cancer-related pain. Mayo Clin Proc 1994;69:384-390.
21. Sawe J, Hansen J, Ginman C, et al. Patient-controlled dose regimen of methadone for chronic cancer pain. BMJ 1981;282:771-778.
22. Inturrisi CE, Colburn WA. Pharmacokinetics of methadone. In: Foley KM, Inturrisi CE, eds. Advances in pain reseach and therapy, vol 8. New York: Raven, 1986:191-199.
23. Ferrer-Brechner T, Ganz P. Combination therapy with ibuprofen and methadone for chronic cancer pain. Am J Med 1984;77:78-92.
24. Max MB, Portenoy RK. Pain research: designing clinical trials in palliative care. In: Doyle D, Hanks GW, MacDonald N, eds. Oxford textbook of palliative medicine. Oxford: Oxford Medical Publications, 1993:77-86.
25. Horns WH, Rado M, Goldstein A. Plasma level and symptom complaints in patients maintained on daily dosage of methadone hydrochloride. Clin Pharmacol Ther 1975;17:636-648.
26. Mercadante S, Sapio M, Serretta R, Caligara M. Oral patient controlled analgesia with methadone in cancer pain. Ann Oncol 1996;7:613-617.
27. Bruera E. Bone pain due to cancer. Refresher Course Syllabus, Seventh World Congress on Pain, August 22-27, IASP publications Paris, 1993:237-244.
28. Portenoy RK. Cancer pain management. Semin Oncol 1993;20(suppl 1):19-35.